BSX stock heads into Wednesday morning's earnings report after Boston Scientific posted $5.20 billion in revenue last quarter and missed forward guidance expectations. The company also fell short on full-year EPS guidance estimates, leaving investors focused on whether the next update shows a slowdown or a reset.
Boston Scientific and Wall Street
Boston Scientific's last quarter showed revenue of $5.20 billion, up 11.6% year on year. The market now expects revenue growth of 5.9% this quarter, well below the 22.8% pace in the same quarter last year. That gap is the main reason Wednesday's report matters to BSX stock holders: the company has already shown it can beat Wall Street, but it is entering this release after weaker guidance.
Analysts covering Boston Scientific have generally reconfirmed their estimates over the last 30 days, so the setup has not shifted much ahead of the print. Boston Scientific's average analyst price target is $72.25, while the current share price is $45.55.
Watchman and Q2
Boston Scientific's prior quarter also carried a separate complication: its revenue guidance for the next quarter missed analysts' expectations significantly. The company has a history of exceeding Wall Street's expectations, which makes the weaker guidance more noticeable than a routine miss. For investors, the issue is not just whether revenue grows again, but whether the pace of that growth matches the slowing pattern already built into forecasts.
Watchman remains part of that read-through because softer demand there is one of the reasons the company trimmed its annual profit forecast in the earlier quarter. The upcoming Q2 report will show whether that pressure eases or continues into the new period. Boston Scientific will report earnings on Wednesday morning, and the stock will react to whether the company can turn a softer guide into a better follow-through number.
Abbott Laboratories and Intuitive Surgical
Recent results from Abbott Laboratories and Intuitive Surgical give a reference point for the sector. Abbott Laboratories delivered year-on-year revenue growth of 13% in its Q2 results and beat analysts' expectations by 0.7%, while Intuitive Surgical reported revenues up 18.5% in its Q2 results and topped estimates by 2.5%.
Those results also moved sharply in different directions in the market, with Abbott Laboratories up 12.8% after its release and Intuitive Surgical down 14.1%. Boston Scientific's own report now becomes the next test for whether BSX stock is being valued on its history of beats or on the slower growth investors are already expecting.
